AZ

Adam Zlotnick

Scientific Advisor at Assembly Biosciences

Adam Zlotnick has a BA in Biology from the University of Virginia and earned his PhD at Purdue University, in 1994, in the lab of Jack Johnson where his thesis topic was the structure and assembly of icosahedral viruses. Dr. Zlotnick went on to be a National Research Council Fellow at the NIH, in the lab of Alasdair Steven, using cryo-EM and solution studies to investigate Hepatitis B virus.

In 1998, Dr Zlotnick took a faculty position at Oklahoma University Health Sciences Center where he was first able to develop approaches to quantitatively observing virus assembly. In 2008, Dr. Zlotnick moved to Indiana University where he is a Professor of Molecular and Cellular Biochemistry. He continues to study the physical chemistry of virus assembly and its structural basis in several systems, particularly HBV. He also works on developing antivirals directed at viral structural proteins. He uses a broad range of structural, physical, and biochemical techniques in his studies.

He co-founded Assembly Pharmaceuticals (now Assembly Biosciences) in 2012 and Door Pharmaceuticals in 2018. He initiated the Gordon Conference series on Physical Virology in 2009. He is a fellow of the American Academy of Microbiology and of the AAAS. He has published more than 130 papers and reviews; he is an inventor on 10 patents and patent applications.

Location

Bloomington, United States

Links


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Assembly Biosciences

9 followers

Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.


Industries

Employees

51-200

Links